Allurion Technologies has raised $27m in a Series C venture financing round led by Romulus Capital. The round has also seen the participation of Cogepa SA and Ibtikar Development Oman SAOC (IDO).
The proceeds will be used by the company for commercialisation and manufacturing activities, as well as to seek clinical trial approval from the US Food and Drug Administration (FDA).
Allurion manufactures a procedure-less weight loss device named the Elipse Balloon.
Molecular device company ImmunArray has signed a partnership agreement with Kindstar Global to conduct joint clinical testing and to launch its lupus Rule-Out test in China.
The partners will conduct clinical testing of up to 500 serum samples collected from healthy Chinese patients and also from those with symptoms of systemic lupus erythematosus (SLE).
Testing will enable clinical implementation of ImmunArray’s SLE-Key Rule-Out test.
The agreement also entitles Kindstar with exclusive marketing rights to the SLE-Key Rule-Out test, which is scheduled to be launched in China in November.
Owlstone Medical has collaborated with Cancer Research UK (CRUK) to develop breath biomarkers that will enable early detection and diagnosis of different types of cancer.
Owlstone and a team of leading cancer researchers at the CRUK Cambridge Centre have initiated the PAN Cancer trial, which will evaluate the use of the company’s breath biopsy platform for early detection of multiple cancer types, including bladder, breast, head and neck, kidney, oesophageal, pancreatic, and prostate cancers.
Sustained-release drug products and technologies developer pSivida has announced an amendment to its exclusive license and collaboration agreement with Alimera Sciences.
Alimera will receive rights to pSivida's Durasert™ in Europe, the Middle East, and Africa (EMEA). pSivida retains commercialisation rights of the product in all other countries, including the US.
Durasert™ is a three-year treatment for posterior segment uveitis (Durasert).
Polish company Braster engaged in developing liquid crystal matrices for breast cancer diagnosis intends to raise between $14.5m and $17m in gross proceeds by issuing three million Series I shares.
The proceeds will be used by the company to expand into foreign markets, to further develop its global telemedicine platform and to purchase real estate assets in Szeligi, Poland.